Trifarotene

• CAT Number: I009882
• CAS Number: 895542-09-3
• Molecular Formula: C29H33NO4
• Molecular Weight: 459.58
• Purity: ≥95%
• Synonyms: Trifarotene;3/’/’-(tert-butyl)-4/’-(2-hydroxyethoxy)-4/’/’-(pyrrolidin-1-yl)-[1,1/’:3/’,1/’/’-terphenyl]-4-carboxylic acid
• Target: gamma retinoic acid receptor agonist
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
• InChI: InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
• InChIKey: MFBCDACCJCDGBA-UHFFFAOYSA-N
• SMILES: CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4

Trifarotene（Cat No.:I009882） is a compound that acts as a selective agonist for the gamma retinoic acid receptor. It is currently being developed as a topical cream for the treatment of various skin disorders. Trifarotene shows promise in the management of acne vulgaris, a common skin condition, as well as cutaneous T-cell lymphoma and lamellar ichthyosis, which are rare skin disorders. As a topical treatment, trifarotene offers a targeted approach for addressing these dermatological conditions, and further research is underway to evaluate its efficacy and safety in clinical settings.